• PDB40 - IMPACT OF DAPAGLIFLOZIN ON REDUCING ECONOMIC BURDEN OF TYPE 2 DIABETES ENHANCEMENT PATIENT’S OUTCOMES AT COUNTRIES WITH HIGH INCIDENCE OF DIABETES EGYPT CASE

    Oct 1, 2018, 00:00

  • PIN111 - IMPACT OF VARIATION IN INFLUENZA VACCINATION SCHEDULES AND DECISION-MAKING CRITERIA ON PATIENT OUTCOMES IN EUROPEAN COUNTRIES

    Oct 1, 2018, 00:00

  • PUK8 - EVALUATION OF PRESCRIBING PRACTICES AND DRUG-RELATED PROBLEMS IN CHRONIC KIDNEY DISEASE PATIENTS- A PROSPECTIVE OBSERVATIONAL STUDY

    Oct 1, 2018, 00:00

  • PCN318 - CONDUCTING AND REPORTING INDIRECT TREATMENT COMPARISONS- A CRITICAL APPRAISAL OF ONCOLOGY TECHNOLOGY APPRAISALS

    Oct 1, 2018, 00:00

  • PCV88 - PHARMACOECONOMICS OF ALIROCUMAB IN TREATMENT OF HYPERCHOLESTEROLEMIA- A SYSTEMATIC REVIEW

    Oct 1, 2018, 00:00

  • PRS42 - COST-EFFECTIVENESS OF INDACATEROL/GLYCOPYRRONIUM IN THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN BRAZIL

    Oct 1, 2018, 00:00

  • PHP96 - TIME EFFICIENCY IN THE REGULATORY DECISION-MAKING PROCESS OF ORPHAN DRUGS

    Oct 1, 2018, 00:00

  • PDB21 - COMPARATIVE EFFECTIVENESS OF SGLT2 INHIBITORS IN TYPE II DIABETES DERIVED FROM AN OVERVIEW OF 55 SYSTEMATIC REVIEWS

    Oct 1, 2018, 00:00

  • PMH63 - ACCESS TO ANTI-DEPRESSANT THERAPIES IN ENGLAND- IS THERE A POSTCODE LOTTERY?

    Oct 1, 2018, 00:00

  • PMD181 - PATIENT PREFERENCE FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATMENT INHALERS- A DISCRETE CHOICE EXPERIMENT (DCE) IN FRANCE

    Oct 1, 2018, 00:00

  • PMH44 - CANADIAN ECONOMIC IMPACT OF IMPROVED WORKPLACE PRODUCTIVITY IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER TREATED WITH VORTIOXETINE

    Oct 1, 2018, 00:00

  • PIN108 - HUMAN PAPILLOMAVIRUS VACCINATION UPTAKE BARRIERS AMONG ADOLESCENTS AND THEIR PARENTS IN THE RUSSIAN FEDERATION

    Oct 1, 2018, 00:00

  • PDB22 - CLINICAL AND DEMOGRAPHIC CHARACTERISTICS OF PATIENTS REACHING A HIGH DAILY DOSE OF IDEGLIRA SIX MONTHS AFTER INITIATION IN A REAL-WORLD SETTING

    Oct 1, 2018, 00:00

  • PMH32 - ECONOMIC IMPACT OF OPIOID DEPENDENCE IN GERMANY- A COST OF ILLNESS STUDY FOCUSSING ON PATIENTS IN OPIOID MAINTENANCE TREATMENT

    Oct 1, 2018, 00:00

  • PCV47 - PHARMACOECONOMIC ANALYSIS OF CHRONIC HEART FAILURE DRUG THERAPY IN PATIENTS WITH COMORBID CONDITIONS

    Oct 1, 2018, 00:00

  • PSY76 - ECONOMIC BURDEN OF DISEASES RELATED TO OVERWEIGHT AND OBESITY IN COLOMBIA

    Oct 1, 2018, 00:00

  • PMU116 - PATIENT-REPORTED OUTCOMES IN A PILOT RANDOMIZED TRIAL OF GENOME SEQUENCING

    Oct 1, 2018, 00:00

  • PMS13 - REAL-WORLD TREATMENT OF PATIENTS WITH OSTEOPOROSIS IN GERMANY- PREVALENCE AND INCIDENCE OF PATIENTS WITH OSTEOPOROSIS AT INCREASED FRACTURE RISK

    Oct 1, 2018, 00:00

  • Estimating a Dutch Value Set for the Pediatric Preference-Based CHU9D Using a Discrete Choice Experiment with Duration

    Oct 1, 2018, 00:00

  • PMH34 - A CONCEPTUAL ECONOMIC MODEL FOR DIGITAL INTERVENTIONS IN SERIOUS MENTAL ILLNESS

    Oct 1, 2018, 00:00

  • PND40 - COST OF HEALTHCARE RESOURCE USE BY PATIENTS WITH MULTIPLE SCLEROSIS IN FRANCE ACCORDING TO DISEASE SEVERITY

    Oct 1, 2018, 00:00

  • PSY182 - A TARGETED REVIEW OF HAEMATOLOGY SINGLE TECHNOLOGY APPRAISALS (STAS) BY NICE SINCE THE INTRODUCTION OF THE NEW CANCER DRUGS FUND (CDF)

    Oct 1, 2018, 00:00

  • PGI10 - COMPARATIVE EFFECTIVENESS OF PAN-GENOTYPIC THERAPIES FOR THE TREATMENT OF PATIENTS WITH HEPATITIS C VIRUS INFECTION IN BULGARIA

    Oct 1, 2018, 00:00

  • PCV30 - REAL WORLD EVIDENCE OF THE RISK OF STROKE OR SYSTEMIC EMBOLISM IN CHRONIC KIDNEY DISEASE PATIENTS WITH ATRIAL FIBRILLATION

    Oct 1, 2018, 00:00

  • PCN378 - MINIMALLY IMPORTANT DIFFERENCES FOR INTERPRETING EORTC QLQ-C30 SCORES IN MELANOMA, BREAST CANCER AND HEAD AND NECK CANCER PATIENTS ON BEHALF OF THE EORTC BREAST, HEAD AND NECK, MELANOMA AND QUALITY OF LIFE GROUPS

    Oct 1, 2018, 00:00

  • PHP118 - IMPACT OF COHORT TEMPORARY AUTHORISATION FOR USE ON PRICE IN FRANCE

    Oct 1, 2018, 00:00

  • PDB86 - COST-UTILITY ANALYSIS OF INSULIN GLARGINE 300 U/ML VERSUS INSULIN GLARGINE 100 U/ML AND INSULIN DEGLUDEC 100 U/ML IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN BULGARIA

    Oct 1, 2018, 00:00

  • PIN101 - ACUTE GASTROENTERITIS HOSPITALIZATIONS- EXPLORING SPATIO-TEMPORAL PATTERNS AND SELF-FINANCED ROTAVIRUS VACCINATION EFFECT

    Oct 1, 2018, 00:00

  • PMD131 - MEDICAL IMAGING EQUIPMENT IN ITALY- STATE OF ART OF INSTALLED BASE AND RENEWAL STRATEGIES

    Oct 1, 2018, 00:00

  • PCN212 - PREVALENCE OF CANCER AMONG WOMEN IN A TERTIARY TEACHING HOSPITAL IN LAGOS SOUTHWEST NIGERIA- A PHARMACOEPIDEMIOLOGICAL AND EVIDENCE BASED SURVEY

    Oct 1, 2018, 00:00

  • PHP93 - THE IMPACT OF SUPPLY CHAIN MARGINS AND VAT ON THE PRICES OF MEDICINES IN BULGARIA AND GREECE

    Oct 1, 2018, 00:00

  • PRM7 - THE USE OF NATURAL LANGUAGE PROCESSING TO ASSESS PATIENTS WITH BLEEDS IN THEIR NOTES IN THE OPTUM EHR DATABASE

    Oct 1, 2018, 00:00

  • PIH2 - CLINICAL AND DEMOGRAPHIC RISK FACTORS AND COSTS OF SURGICAL SITE INFECTION FOLLOWING HYSTERECTOMY

    Oct 1, 2018, 00:00

  • PSY207 - IS LATE NIGHT EATING LINKED TO CHILDHOOD OBESITY? A SYSTEMATIC REVIEW

    Oct 1, 2018, 00:00

  • PMS43 - AN ECONOMIC VALUE FRAMEWORK TO ASSESS THE COST EFFECTIVENESS OF FRACTURE PREVENTION TREATMENTS IN PATIENTS WITH OSTEOPOROSIS AT IMMINENT RISK OF FRACTURE

    Oct 1, 2018, 00:00

  • PUK35 - WORK PRODUCTIVITY AND EQ-5D UTILITY OF PATIENTS WITH CHRONIC KIDNEY DISEASE BY ANEMIA SEVERITY- POOLED RESULTS FROM THREE CROSS-SECTIONAL INTERNATIONAL SURVEYS

    Oct 1, 2018, 00:00

  • PCN185 - COST-EFFECTIVENESS OF NIVOLUMAB IN SECOND-LINE TREATMENT OF LOCALLY ADVANCED UNRESECTABLE OR METASTATIC UROTHELIAL CARCINOMA IN ADULTS AFTER FAILURE OF PRIOR PLATINUM-CONTAINING THERAPY IN GREECE

    Oct 1, 2018, 00:00

  • PDB100 - STUDY ON AWARENESS REGARDING NEWER TRENDS IN DIABETES MEDICATION MANAGEMENT

    Oct 1, 2018, 00:00

  • PCN268 - TREATMENTS AND HEALTH CARE UTILISATION (HCU) IN PATIENTS WITH RECURRENT OR METASTATIC (R/M) HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC) FOLLOWING INITIAL PLATINUM THERAPY IN THE UNITED KINGDOM

    Oct 1, 2018, 00:00

  • PND10 - GENIUS RWE STUDY (FINGOLIMOD REAL WORLD EVIDENCE ITALIAN MULTICENTER OBSERVATIONAL STUDY IN MULTIPLE SCLEROSIS)PRELIMINARY RESULTS

    Oct 1, 2018, 00:00

  • PND62 - COST-EFFECTIVENESS OF CLADRIBINE TABLETS IN THE TREATMENT OF PATIENTS WITH HIGHLY ACTIVE RELAPSING MULTIPLE SCLEROSIS IN PORTUGAL

    Oct 1, 2018, 00:00

  • PRM65 - DIFFERENT COST EFFECTIVENESS MODELS USED FOR ECONOMIC EVALUATION IN MODERATE TO SEVERE PAINFUL DIABETIC NEUROPATHY OR POST-HERPETIC NEURALGIA

    Oct 1, 2018, 00:00

  • PCV112 - PATTERN OF USE OF ANTIHYPERTENSIVE DRUGS IN TWO EUROPEAN COUNTRIES- COMPARISON OF THE INDEX THERAPIES AND PERSISTENCE

    Oct 1, 2018, 00:00

  • PHP281 - THE METHODOLOGICAL DIFFERENCES OF EUROPEAN JOINT ASSESSMENT AND GERMAN HTA- AN EMPIRICAL APPROACH

    Oct 1, 2018, 00:00

  • PND36 - COSTS OF MULTIPLE SCLEROSIS IN DENMARK- A REGISTER BASED STUDY

    Oct 1, 2018, 00:00

  • PMS33 - CATEGORISING PATIENTS WITH RHEUMATOID ARTHRITIS USING TRAJECTORIES OF DISEASE ACTIVITY SCORE IN HUNGARY

    Oct 1, 2018, 00:00

  • CV1 - A COST-EFFECTIVENESS ANALYSIS OF MULITI-GENE PHARMACOGENETIC TESTING IN ACUTE CORONARY SYNDROME PATIENTS FOLLOWING PERCUTANEOUS CORONARY INTERVENTION

    Oct 1, 2018, 00:00

  • PDB84 - HETEROGENEITY OF TREATMENT EFFECT IN THE DIABETES PREVENTION PROGRAM- HIGH BASELINE RISK OF DEVELOPING DIABETES MAY PROVIDE A PLACE FOR METFORMIN IN DIABETES PREVENTION THAT USING OVERALL SAMPLE AVERAGE COSTS AND EFFECTS CONCEALS

    Oct 1, 2018, 00:00

  • PSY203 - DESCRIPTIVE EPIDEMIOLOGY OF OBESITY IN A REAL WORLD POPULATION OF ADULTS IN THE UNITED STATES- 2010 - 2017

    Oct 1, 2018, 00:00

  • PHP266 - MANAGED ACCESS PROGRAMS- A FIRST STEP FOR UK HTA?

    Oct 1, 2018, 00:00

  • PCN244 - REAL-WORLD EVIDENCE ON THE UTILISATION OF REGORAFENIB IN IRELAND

    Oct 1, 2018, 00:00

  • PMH52 - THERAPEUTIC STRATEGIES UTILIZED IN PATIENTS TREATED FOR DEPRESSION IN AN ITALIAN REAL-WORLD SETTING, VENETO REGION.

    Oct 1, 2018, 00:00

  • PIH3 - CLINICAL AND DEMOGRAPHIC RISK FACTORS AND COSTS OF SURGICAL SITE INFECTION AFTER CAESAREAN SECTION

    Oct 1, 2018, 00:00

  • PRM234 - HAZARD RATIO ESTIMATION USING DIFFERENT METHODS- AN IMPACT ASSESSMENT

    Oct 1, 2018, 00:00

  • PRM197 - RESPONDER DEFINITION OF THE MULTIPLE SCLEROSIS IMPACT SCALE (MSIS)-29 V2 AMONG PATIENTS WITH SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS

    Oct 1, 2018, 00:00

  • PDB124 - PERSONALIZED DIABETES MANAGEMENT- WHAT DO PATIENTS WITH DIABETES MELLITUS PREFER?

    Oct 1, 2018, 00:00

  • PHP62 - HOME BREWED AUTOLOGOUS THERAPIES- CAN BIOPHARMA WIN THE WAR WITH DOMESTIC AUTOLOGOUS CELL GENE THERAPY MANUFACTURERS?

    Oct 1, 2018, 00:00

  • PHP154 - PRIVATE HEALTH SPENDING AND ACCESS TO HEALTHCARE OF UNEMPLOYED PEOPLE IN GREECE

    Oct 1, 2018, 00:00

  • PMD117 - POINT-OF-CARE TESTING IN PRIMARY CARE- A SYSTEMATIC REVIEW OF TEST EVALUATIONS AND AVAILABLE EVIDENCE

    Oct 1, 2018, 00:00

  • PHP306 - CAN GRADEPRO SUPPORT AND IMPROVE CHOICE OF OUTCOMES IN HEALTH TECHNOLOGY ASSESSMENT? REPORT ON A PILOT USE WITHIN THE EUNETHTA ASSESSMENT OF FEMTOSECOND LASER ASSISTED CATARACT SURGERY (FLACS)

    Oct 1, 2018, 00:00

  • PSY153 - UNDERSTANDING PATTERNS OF 30-DAY READMISSION IN PATIENTS WITH CARDIAC AMYLOIDOSIS

    Oct 1, 2018, 00:00

  • PCN387 - COMPARISON OF EQ-5D-5L AND 15D INSTRUMENTS IN ASSESSING HEALTH-RELATED QUALITY OF LIFE IN BREAST CANCER PATIENTS

    Oct 1, 2018, 00:00

  • PRM55 - A NEW ANALYSIS METHODOLOGY TO FIND ATYPICAL COST PROFILES IN PATIENTS LIVING WITH HIV FROM A NATIONAL CLAIM INSURANCE DATA (SNIIRAM)

    Oct 1, 2018, 00:00

  • PCN231 - PRICING, AVAILABILITY, AFFORDABILITY, PRICE COMPONENTS OF ESSENTIAL ANTICANCER MEDICINES IN ADDIS ABABA, ETHIOPIA

    Oct 1, 2018, 00:00

  • PCN67 - BUDGET IMPACT MODEL OF SUBCUTANEOUS RITUXIMAB COMPARED WITH INTRAVENOUS RITUXIMAB ON THE TREATMENT OF CD-20 POSITIVE NON-HODGKIN LYMPHOMA IN THE BRAZILIAN PRIVATE HEALTHCARE SYSTEM

    Oct 1, 2018, 00:00

  • PCN138 - COST-EFFECTIVENESS ANALYSIS OF PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY TREATED LOCALLY ADVANCED OR METASTATIC UROTHELIAL CANCER IN ENGLAND

    Oct 1, 2018, 00:00

  • PUK31 - THE BURDEN ASSOCIATED WITH IMMUNOGLOBULIN A NEPHROPATHY(IGAN)

    Oct 1, 2018, 00:00

  • PCV41 - COST IMPACT ANALYSIS OF USING IMPROVE® TOOL FOR VENOUS THROMBOEMBOLISM RISK ASSESSMENT IN MEDICAL PATIENTS ADMITTED TO THE UK NHS HOSPITALS TO INFORM NICE CLINICAL GUIDELINE RECOMMENDATION

    Oct 1, 2018, 00:00

  • PHP264 - QUALITATIVE ANALYSIS OF CLINICAL TRIALS RELATED TO DIABETES REGISTERED WITH CLINICAL TRIAL REGISTRY OF INDIA

    Oct 1, 2018, 00:00

  • A Generic Model for Follicular Lymphoma- Predicting Cost, Life Expectancy, and Quality-Adjusted-Life-Year Using UK Population–Based Observational Data

    Oct 1, 2018, 00:00

  • PMD32 - HOW CHANGES IN ELECTROCARDIOGRAPHY MONITORING AND REIMBURSEMENT PRACTICES COULD IMPACT ON SURGICAL SITE INFECTIONS AFTER CORONARY ARTERY BYPASS GRAFT SURGERY

    Oct 1, 2018, 00:00

  • PND11 - INDIRECT TREATMENT COMPARISON OF AVXS-101 TO NUSINERSEN FOR THE TREATMENT OF TYPE 1 SPINAL MUSCULAR ATROPHY

    Oct 1, 2018, 00:00

  • PIN71 - ADENOVIRUS VIREMIA IS AN INDEPENDENT PREDICTOR OF PROLONGED TRANSPLANTATION HOSPITALIZATION IN PEDIATRIC ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT RECIPIENTS- FINDINGS FROM ADVANCE

    Oct 1, 2018, 00:00

  • PSY27 - SPINAL MUSCULAR ATROPHY- A REVIEW OF EPIDEMIOLOGY, BURDEN AND UNMET NEEDS

    Oct 1, 2018, 00:00

  • PMD178 - GLOBAL BURDEN OF PRESBYOPIA- A SYSTEMATIC LITERATURE REVIEW

    Oct 1, 2018, 00:00

  • PMD161 - CLINICAL IMPACT OF A PHARMACEUTICAL PROFESIONAL SERVICE INTERVENTION WITH OR WITHOUT A MULTI-COMPARTMENT MEDICATION IN NON-ADHERENT, UNCONTROLLED, CHRONIC HYPERTENSIVE, POLYMEDICATED PATIENTS IN SPANISH COMMUNITY PHARMACIES. SEFAC- ...

    Oct 1, 2018, 00:00

  • PMD16 - HEALTH ECONOMIC EVALUATION OF AN ULTRATHIN, BIORESORBABLE POLYMER SIROLIMUS-ELUTING CORONARY STENT COMPARED TO A THIN, DURABLE POLYMER EVEROLIMUS-ELUTING STENT

    Oct 1, 2018, 00:00

  • PCN341 - ESTIMATION OF UTILITIES ON SKELETAL-RELATED EVENTS (SRE) IN PATIENTS WITH BONE METASTATIC CANCER IN KOREA

    Oct 1, 2018, 00:00

  • PRS24 - INFORMING THE PATHWAY OF COPD TREATMENT (IMPACT STUDY) - SINGLE INHALER TRIPLE THERAPY (FF/UMEC/VI) VERSUS FF/VI AND UMEC/VI IN PATIENTS WITH COPD- HEALTHCARE RESOURCE UTILIZATION DATA AND ASSOCIATED COSTS – GERMANY

    Oct 1, 2018, 00:00

  • PGI15 - HEALTHCARE RESOURCE UTILIZATION (HCRU) IN METASTATIC OR UNRESECTABLE GASTRIC OR GASTROESOPHAGEAL JUNCTION CANCER PATIENTS RECEIVING SECOND-LINE TREATMENT

    Oct 1, 2018, 00:00

  • PIH54 - A GLOBAL REVIEW OF QUALITY OF LIFE IMPACT OF ATOPIC DERMATITIS IN CHILDREN

    Oct 1, 2018, 00:00

  • PDB11 - CHART REVIEW ANALYSIS OF INSULIN GLARGINE 300 AND INSULIN GLARGINE 100 USE IN FRANCE, SPAIN, AND GERMANY

    Oct 1, 2018, 00:00

  • PMS5 - A NETWORK META-ANALYSIS TO EVALUATE THE EFFICACY OF BARICITINIB AND OTHER TREATMENTS OF RHEUMATOID ARTHRITIS IN PATIENTS WHO ARE INADEQUATE RESPONDERS TO METHOTREXATE

    Oct 1, 2018, 00:00

  • PMU88 - HEALTH EXPECTANCIES FROM CLINICAL DATA- AN ALTERNATIVE TO THE SULLIVAN METHOD?

    Oct 1, 2018, 00:00

  • PCN73 - BUDGET IMPACT OF IXAZOMIB IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA IN RUSSIA

    Oct 1, 2018, 00:00

  • PSS66 - IDENTIFYING THE MOST SUITABLE QUALITY OF LIFE ASSESSMENT TOOLS TO MEASURE HUMANISTIC BURDEN OF ACUTE OTITIS MEDIA IN CHILDREN

    Oct 1, 2018, 00:00

  • PSY178 - FACTORS ASSOCIATED WITH OBESITY IN GREECE

    Oct 1, 2018, 00:00

  • PMD95 - ECONOMIC EVALUATION OF STRATEGIES WITH/WITHOUT P16 FOR OPPORTUNISTIC CERVICAL CANCER SCREENING

    Oct 1, 2018, 00:00

  • PHP270 - POPULARITY OF NURSING PROFESSION AMONGST STUDENTS WHO ARE BEFORE THE CAREER CHOICE

    Oct 1, 2018, 00:00

  • PCP50 - PERFORMANCE INDICATORS IN THE MONITORING OF OUTSOURCED PUBLIC HEALTH SERVICES

    Oct 1, 2018, 00:00

  • PCN370 - COMPARISONS ON THE CHANGE OF PSYCHOSOCIAL ILLNESS IMPACT ACROSS FOUR CANCER SURVIVORS

    Oct 1, 2018, 00:00

  • PCN152 - COST EFFECTIVENESS OF ALECTINIB IN THE FIRST LINE TREATMENT OF ADVANCED ALK-POSITIVE NON-SMALL CELL LUNG CANCER IN TURKEY

    Oct 1, 2018, 00:00

  • PDB61 - COST-EFFECTIVENESS ANALYSIS OF HUMAN OR ANALOGUE BASAL INSULIN-SUPPORTED ORAL THERAPY IN TYPE 2 DIABETES IN HUNGARY

    Oct 1, 2018, 00:00

  • PMH24 - COST IMPLICATIONS OF ANTIPSYCHOTICS DRUGS- A HOSPITAL BUDGET IMPACT MODEL

    Oct 1, 2018, 00:00

  • PMD126 - DO OUTCOMES DIFFER BY THE TYPE OF ACUTE ISCHEMIC DIAGNOSIS? A RETROSPECTIVE ANALYSIS OF US HOSPITAL DATABASE

    Oct 1, 2018, 00:00

  • PRM171 - DETERMINANTS OF THE ACCEPTABILITY OF HEALTH PROBLEMS IN DIFFERENT AGES- EXPLORING A NEW APPLICATION OF THE EQ VAS

    Oct 1, 2018, 00:00

  • PMS47 - COST-EFFECTIVENESS OF TOFACITINIB COMPARED WITH ADALIMUMAB IN THE TREATMENT OF MODERATE TO SEVERE RHEUMATOID ARTHRITIS IN IRAN

    Oct 1, 2018, 00:00

  • PRS29 - COST ANALYSIS OF AN ERROR TARGETED INTERVENTION TO REDUCE OR ERADICATE INHALER ERRORS IN ASTHMA PATIENTS IN THE UK

    Oct 1, 2018, 00:00

  • PMD23 - EASYPOD™ CONNECT OBSERVATIONAL STUDY (ECOS) – FRENCH CASE HISTORIES AND GROWTH OUTCOMES

    Oct 1, 2018, 00:00

  • PCN164 - THE APPLICATION OF A RESPONSE-BASED MODELLING APPROACH WITH A LANDMARK POINT- IMPLICATIONS AND CHALLENGES FOR THE ECONOMIC EVALUATION OF NIVOLUMAB FOR ADVANCED/METASTATIC UROTHELIAL CARCINOMA IN THE UK

    Oct 1, 2018, 00:00

  • PRS54 - COST-EFFECTIVENESS ANALYSIS OF RESLIZUMAB FOR PATIENTS WITH SEVERE EOSINOPHILIC ASTHMA INADEQUATELY CONTROLLED WITH HIGH-DOSE INHALED CORTICOSTEROIDS AND LONG-ACTING B2-AGONISTS IN SOUTH KOREA

    Oct 1, 2018, 00:00

  • PCV44 - EFFECTIVENESS OF SACUBITRIL/VALSARTAN VERSUS ENALAPRIL IN REDUCING MORTALITY AND HOSPITALIZATIONS COSTS FROM A MOROCCAN HOSPITAL PERSPECTIVE

    Oct 1, 2018, 00:00

  • PND129 - SATISFACTION AND EXPERIENCES OF PATIENTS TAKING FINGOLIMOD AND INVOLVED IN A PHARMACY-BASED PATIENT SUPPORT PROGRAM – SATFINO QUALITATIVE STUDY

    Oct 1, 2018, 00:00

  • PMH59 - IDENTIFYING THE ASSOCIATION BETWEEN OUTCOMES AND QUALITY OF LIFE (QOL) OR HEALTH CARE RESOURCE UTILISATION (HCRU) IN SCHIZOPHRENIA- A SYSTEMATIC LITERATURE REVIEW (SLR)

    Oct 1, 2018, 00:00

  • PHP19 - ANALYSIS OF ONE-DAY SURGERY INTERVENTIONS AMONG PATIENTS UNDER THE AGE OF 18 IN HUNGARY

    Oct 1, 2018, 00:00

  • PRS45 - COST-EFFECTIVENESS OF BEDAQUILINE VERSUS INJECTABLE STANDARD-OF-CARE AGENTS FOR THE TREATMENT OF DRUG-RESISTANT TUBERCULOSIS (DR-TB) IN RUSSIA, INDIA, AND SOUTH AFRICA- BREAKTHROUGH INNOVATION DRIVING DOWN COST OF TREATMENT SUCCESS

    Oct 1, 2018, 00:00

  • PMU96 - DUTCH HEALTH STATE UTILITIES FOR INFERTILITY AND SUBFERTILITY

    Oct 1, 2018, 00:00

  • PRS23 - PERSISTENCE TO COPD THERAPIES AND IMPACT ON COSTS RELATED TO HEALTHCARE CONSUMPTION- A FRENCH CLAIMS DATA STUDY

    Oct 1, 2018, 00:00

  • PHP307 - REIMBURSEMENT OF ADVANCED THERAPY MEDICINAL PRODUCTS IN EUROPE

    Oct 1, 2018, 00:00

  • PRS43 - COST-EFFECTIVENESS OF DOXYCYCLINE VERSUS PLACEBO IN OUTPATIENT-TREATED ACUTE EXACERBATIONS OF COPD- A DOUBLE-BLIND RANDOMIZED CONTROLLED TRIAL

    Oct 1, 2018, 00:00

  • PDB59 - COST-EFFECTIVENESS OF SWITCHING TO INSULIN DEGLUDEC (IDEG) U100 FROM CURRENTLY AVAILABLE BASAL INSULINS IN BELGIUM BASED ON EVIDENCE FROM REAL-WORLD CLINICAL PRACTICE

    Oct 1, 2018, 00:00

  • PCP34 - BIOSIMILARS- WHAT’S THE ISSUE?

    Oct 1, 2018, 00:00

  • PND134 - THE EFFECT OF PHYSICAL ACTIVITY ON THE MOTOR ASPECTS OF DAILY LIVING OF PARKINSON’S DISEASE PATIENTS

    Oct 1, 2018, 00:00

  • PMU122 - PATIENT-REPORTED OUTCOMES ON PERCEIVED WELL-BEING AMONG PATIENTS ON ANTI-INFLAMMATORY TREATMENT

    Oct 1, 2018, 00:00

  • PSS60 - UTILITY ASSESSMENT FOR PEMPHIGUS HEALTH STATES USING VISUAL ANALOGUE SCALE AND TIME TRADE-OFF METHODS

    Oct 1, 2018, 00:00

  • PRM204 - PSYCHOMETRIC EVALUATION OF EORTC QLQ-C30 IN CUBAN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER

    Oct 1, 2018, 00:00

  • PMS65 - MYOTONIC DISORDERS- ANALYSIS FROM THE FRENCH DRG-BASED INFORMATION SYSTEM (PMSI)

    Oct 1, 2018, 00:00

  • PMD167 - HEALTH TECHNOLOGY ASSESSMENT OF MOBILE HEALTH APPLICATIONS- SLOW PROGRESS IN A FAST-PACED INDUSTRY?

    Oct 1, 2018, 00:00

  • PRM256 - ADJUSTMENT FOR THE IMPACT OF SUBSEQUENT THERAPIES NOT AVAILABLE IN UK ON OVERALL SURVIVAL (OS) IN CASTOR TRIAL- A SUBGROUP ANALYSIS IN SECOND-LINE (2L) PATIENTS

    Oct 1, 2018, 00:00

  • PIN23 - CLINICAL AND ECONOMIC BURDEN OF INVASIVE MENINGOCOCCAL DISEASE IN FRANCE

    Oct 1, 2018, 00:00

  • PCV96 - HEALTHCARE RESOURCE UTLISATION IN PATIENTS ON LIPID-LOWERING THERAPIES OUTSIDE OF WESTERN EUROPE- FINDINGS OF THE INTERNATIONAL CHOLESTEROL MANAGEMENT PRACTICE STUDY (ICLPS)

    Oct 1, 2018, 00:00

  • PCN39 - ESTIMATING THE MEAN PROGRESSION-FREE SURVIVAL OF NIRAPARIB, OLAPARIB AND RUCAPARIB COMPARED TO ROUTINE SURVEILLANCE FOR THE MAINTENANCE TREATMENT OF ADULT PATIENTS WITH RECURRENT OVARIAN CANCER WITHOUT A BRCA MUTATION

    Oct 1, 2018, 00:00

  • PMH60 - A COST-UTILITY ANALYSIS OF A MENTAL HEALTH PROMOTION PROGRAM IN SOCIAL ECONOMY COMPANIES IN FLANDERS

    Oct 1, 2018, 00:00

  • PRS57 - ECONOMIC EVALUATION OF SINGLE INHALER TRIPLE THERAPY FOR PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) USING THE GALAXY MODEL

    Oct 1, 2018, 00:00

  • PCN236 - IMPLICATIONS OF THE FAST EVOLVING THERAPEUTIC LANDSCAPE ON APPROPRIATE COMPARATORS IN ONCOLOGICAL AMNOG BENEFIT ASSESSMENTS

    Oct 1, 2018, 00:00

  • PCN299 - A REVIEW OF APPRAISAL TIMELINES IN ONCOLOGY- DOES REIMBURSEMENT THROUGH THE CANCER DRUGS FUND (CDF) DELAY PATIENT ACCESS?

    Oct 1, 2018, 00:00

  • PMU26 - BUDGET IMPACT ANALYSIS OF INTRAVENOUS BIOSIMILARS COMPARED WITH INTRAVENOUS ORIGINATORS AND SUBCUTANEOUS PRODUCTS

    Oct 1, 2018, 00:00

  • PRM120 - GRAPHICAL USER-FRIENDLY INTERFACE FOR COMPLEX HEALTH ECONOMIC MODELS BUILT IN R

    Oct 1, 2018, 00:00

  • PGI4 - REAL-WORLD TRENDS IN CLINICAL CHARACTERISTICS OF INFLAMMATORY BOWEL DISEASE (IBD) PATIENTS INITIATING VEDOLIZUMAB OVER TIME IN ISRAEL

    Oct 1, 2018, 00:00

  • PCV24 - SAFETY AND EFFECTIVENESS OF CONTEMPORARY P2Y12 INHIBITORS IN EAST ASIAN PATIENTS WITH ACUTE CORONARY SYNDROMES- A NATIONWIDE POPULATION-BASED COHORT STUDY

    Oct 1, 2018, 00:00

  • PCN131 - ASSESSING THE REAL-WORLD COST OF CARE IN PATIENTS WITH METASTATIC TRIPLE NEGATIVE BREAST CANCER (MTNBC) IN THE UNITED STATES

    Oct 1, 2018, 00:00

  • PCN170 - COST-EFFECTIVENESS OF TISAGENLECLEUCEL IN PEDIATRIC AND YOUNG ADULT PATIENTS WITH RELAPSED OR REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA- A CANADIAN SOCIETAL PERSPECTIVE

    Oct 1, 2018, 00:00

  • PMS48 - COST PER RESPONDER ANALYSIS FOLLOWING A 24-WEEK PSORIATIC ARTHRITIS TREATMENT WITH SECUKINUMAB VERSUS ETANERCEPT FROM THE PORTUGUESE PAYER PERSPECTIVE

    Oct 1, 2018, 00:00

  • PRM267 - WHAT IS DRIVING NICE-DECISION MAKING ON SINGLE-ARM TRIALS?

    Oct 1, 2018, 00:00

  • PHP314 - THE RISE OF NICE ADVICE ON THE USE OF PHARMACEUTICALS, MEDICAL DEVICES AND DIGITAL HEALTH CARE IN THE NHS

    Oct 1, 2018, 00:00

  • PHP295 - REVIEW OF POSSIBLE CAUSES OF VARIATION IN NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE (NICE) TECHNOLOGY APPRAISALS

    Oct 1, 2018, 00:00

  • PCP30 - COMPARISON REGARDING THE TRANSPARENCY OF REIMBURSEMENT DECISIONS FOR PHARMACEUTICALS USED TO TREAT DEPRESSION IN HUNGARY, ROMANIA, TURKEY AND CIS

    Oct 1, 2018, 00:00

  • PCV94 - NUTILIS CLEAR® IN DYSPHAGIC ADULT STROKE PATIENTS WITH ASPIRATION OF 10–14 POINTS ON GUSS SCALE

    Oct 1, 2018, 00:00

  • PHP97 - NONADHERENCE TO TACROLIMUS IN ADULT LIVER AND KIDNEY TRANSPLANTATION IS ASSOCIATED WITH A HIGHER RISK OF EFFICACY FAILURE- REAL-WORLD EVIDENCE FROM ITALIAN ADMINISTRATIVE DATABASES

    Oct 1, 2018, 00:00

  • PSY146 - SERIOUS ADVERSE REACTIONS REPORTED FOR DRUGS INVOLVED IN LAWSUITS FILED AGAINST THE BRAZILIAN PUBLIC HEALTH SYSTEM

    Oct 1, 2018, 00:00

  • PND148 - DEVELOPMENT OF A DIGITAL APP AND INNOVATIVE RECRUITMENT FOR AN INTERNATIONAL REAL-WORLD OBSERVATIONAL STUDY IN CHARCOT MARIE TOOTH DISEASE

    Oct 1, 2018, 00:00

  • PCV150 - HEALTH CARE RESOURCE USE AND QUALITY OF LIFE IN PATIENTS PRESCRIBED WITH SACUBITRIL/VALSARTAN IN PORTUGAL- A CROSS-SECTIONAL OBSERVATIONAL STUDY (PRIME STUDY)

    Oct 1, 2018, 00:00

  • PCV37 - IDENTIFICATION OF FACTORS AFFECTING READMISSIONS IN HEART FAILURE PATIENTS

    Oct 1, 2018, 00:00

  • PCN291 - MARKET ACCESS FOR ONCO-HEMATOLOGY MEDICINES - VALUE OF SINGLE ARM STUDIES - ANALYSIS OF FRENCH HTA OPINIONS

    Oct 1, 2018, 00:00

  • PDB25 - PRESCRIBING PATTERN IN DIABETES MELLITUS PATIENTS IN SLOVENIA

    Oct 1, 2018, 00:00

  • PHP333 - ADDRESSING THE CHALLENGE OF CHRONICITY IN A REGION OF SPAIN. TAKING STEPS TOWARDS A PARTNERSHIP BETWEEN THE HEALTH CARE ADMINISTRATION AND THE PHARMACEUTICAL INDUSTRY

    Oct 1, 2018, 00:00

  • PHP132 - CAN BLOCKCHAIN TECHNOLOGY IMPROVE THE QUALITY OF CLINICAL TRIAL EVIDENCE? – A SYSTEMATIC LITERATURE REVIEW

    Oct 1, 2018, 00:00

  • PHP311 - UPTAKE OF JOINTLY PRODUCED EUNETHTA HEALTH TECHNOLOGY ASSESSMENTS- WHERE ARE WE NOW?

    Oct 1, 2018, 00:00

  • PHP21 - METHODOLOGY OF IDENTIFICATION OF RISK GROUPS UNDER PHARMACEUTICAL GUIDELINES IN A SPECIAL REGIME INSURER IN COLOMBIA

    Oct 1, 2018, 00:00

  • PCN88 - NET IMPACT ANALYSIS OF IXAZOMIB IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE IN THE TREATMENT OF ADULTS WITH MULTIPLE MYELOMA FOR QUEBEC

    Oct 1, 2018, 00:00

  • PSY218 - SYMPTOM AND IMPACT DISTURBANCE- FINDINGS FROM A QUALITATIVE ASSESSMENT OF PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML)

    Oct 1, 2018, 00:00

  • PHP361 - PIM AND EAMS- THE IMPACT OF PROMISING MEDICINE DESIGNATION IN ACHIEVING PATIENT ACCESS

    Oct 1, 2018, 00:00

  • PRM42 - COST MODEL OF SWITCHING FROM ENBREL TO ETANERCEPT BIOSIMILARS, FOR NON MEDICAL REASONS, IN RHEUMATOID ARTHRITIS PATIENTS IN SPAIN

    Oct 1, 2018, 00:00

  • PMS77 - DECLINE IN HEALTHCARE RESOURCE CONSUMPTION FOR PATIENTS WITH RHEUMATOID ARTHRITIS STARTING CERTOLIZUMAB PEGOL THERAPY IN FRANCE (THE ECLAIR STUDY)

    Oct 1, 2018, 00:00

  • Development of a Patient-Reported Outcome Measure for Geriatric Care- The Older Persons and Informal Caregivers Survey Short Form

    Oct 1, 2018, 00:00

  • PDB85 - A 10 YEAR COST-EFFECTIVENESS ANALYSIS (CEA) OF THE DIABETES PREVENTION PROGRAM OUTCOMES STUDY (DPP/DPPOS)- CLARIFYING THE PREVIOUS CONFUSION

    Oct 1, 2018, 00:00

  • PHP344 - AN ECONOMIC EVALUATION OF GENERIC DRUG ENTRIES IN TURKISH PHARMACEUTICAL MARKET

    Oct 1, 2018, 00:00

  • QL3 - EQ-5D-5L IS MORE RESPONSIVE THAN EQ-5D-3L TO TREATMENT BENEFIT OF CATARACT SURGERY

    Oct 1, 2018, 00:00

  • PMU5 - THE ROLE OF MULTIMORBIDITY ON EARLY RETIREMENT IN EUROPE - RESULTS FROM THE SURVEY OF HEALTH, AGEING AND RETIREMENT IN EUROPE (SHARE)

    Oct 1, 2018, 00:00

  • PCN369 - RELATION OF HEALTH RELATED QUALITY OF LIFE WITH INDICATORS OF NUTRITIONAL STATUS IN HEAD AND NECK CANCER PATIENTS ATTENDED IN A MEXICAN THIRD LEVEL PUBLIC FACILITY

    Oct 1, 2018, 00:00

  • PUK39 - A CRITICAL APPRAISAL OF THE PRINCIPAL GUIDELINES FOR NEUROGENIC LOWER URINARY TRACT DYSFUNCTION USING THE AGREE II INSTRUMENT

    Oct 1, 2018, 00:00

  • PCV69 - COST-EFFECTIVENESS OF IVABRADINE AS A PHARMACOTHERAPY OPTION FOR PATIENTS WITH CONGESTIVE HEART FAILURE- A SYSTEMATIC REVIEW

    Oct 1, 2018, 00:00

  • PHP345 - INNOVATIVE PAYMENT MODELS FOR BREAKTHROUGH THERAPIES

    Oct 1, 2018, 00:00

  • PCN121 - BSC COST IN TERMINAL CANCER PATIENTS IN KOREA

    Oct 1, 2018, 00:00

  • PMS71 - SECULAR TRENDS IN THE INITIATION OF THERAPY IN SECONDARY FRACTURE PREVENTION IN EUROPE- A MULTI-NATIONAL STUDY INCLUDING DATA FROM DENMARK, SPAIN, AND THE UK.

    Oct 1, 2018, 00:00

  • PMS87 - IMPACT OF SERIOUS ILLNESS MEDICAL ASSISTANCE POLICY ON PERSISTENCE WITH TERIPARATIDE IN OSTEOPOROSIS PATIENTS IN QINGDAO, CHINA

    Oct 1, 2018, 00:00

  • PCN110 - COSTS ASSOCIATED WITH TRACHEA, BRONCHUS AND LUNG CANCER IN RUSSIA IN 2016 YEAR

    Oct 1, 2018, 00:00

  • PSY60 - ORPHAN VERSUS ULTRA-ORPHAN DRUGS PRICES IN ENGLAND

    Oct 1, 2018, 00:00

  • PRM128 - VALIDATION AND CONCEPTUAL DESIGN OF A HEALTH ECONOMIC MODEL FOR ANAEMIA TREATMENT IN MYELODYSPLASTIC SYNDROME

    Oct 1, 2018, 00:00

  • HT4 - PAN-EUROPEAN HTA – WHERE WE HAVE BEEN, WHERE WE ARE GOING?

    Oct 1, 2018, 00:00

  • PDB66 - INSULIN GAP IN TYPE 2 DIABETES- IS IT COST EFFECTIVE TO INTENSIFY TREATMENT? EVIDENCE FROM PORTUGAL USING REAL WORLD DATA

    Oct 1, 2018, 00:00

  • PCN106 - ECONOMIC BURDEN OF END-OF-LIFE AGGRESSION IN LUNG CANCER PATIENTS FROM THE FRENCH HEALTH INSURER PERSPECTIVE

    Oct 1, 2018, 00:00

  • PHP119 - DISRUPTION IN PATIENT ACCESS TO INNOVATIVE THERAPY IN FRANCE AFTER INTERRUPTION OF NOMINATIVE TEMPORARY AUTHORISATION FOR USE

    Oct 1, 2018, 00:00

  • PND7 - AN EXPLORATORY ANALYSIS OF EFFICACY OF OCRELIZUMAB FOR MULTIPLE SCLEROSIS PATIENTS WITH INCREASED DISABILITY

    Oct 1, 2018, 00:00

  • PRM209 - HOW DO WE MEASURE UTILITIES OUTSIDE OF TRIALS IN RARE DISEASES?

    Oct 1, 2018, 00:00

  • PCV135 - NON-VITAMIN K ANTAGONIST ORAL ANTICOAGULANTS PRESCRIPTION MONITORING- HOW TO OPTIMIZE VIGILANCE IN STROKE PREVENTION

    Oct 1, 2018, 00:00

  • PCN82 - BUDGET IMPACT ANALYSIS OF ALECTINIB FOR THE TREATMENT OF PATIENTS WITH UNTREATED ALK-REARRANGED NSCLC IN ITALY

    Oct 1, 2018, 00:00

  • PMD48 - COSTS IN THE DIAGNOSIS OF SPANISH PATIENTS WITH SUSPECTED RHEUMATOID ARTHRITIS DEPENDS ON THE CCP ASSAY USED – A COMPARISON OF AUTOMATED CCP 2 AND CCP 3 ASSAYS

    Oct 1, 2018, 00:00

  • PCN255 - CERVICAL AND BREAST CANCER IN KAZAKHSTAN BEFORE AND AFTER THE INTRODUCTION OF SCREENING- AN INTERRUPTED TIME SERIES ANALYSIS

    Oct 1, 2018, 00:00

  • PRS38 - COST-CONSEQUENCE ANALYSIS OF FLUTICASONE FUROATE/VILANTEROL FOR ASTHMA MANAGEMENT IN SPAIN- AN ANALYSIS BASED ON THE SALFORD LUNG STUDY IN ASTHMA

    Oct 1, 2018, 00:00

  • PRM140 - UTILIZING ADVANCED DATA ANALYSIS AND VISUALIZATION, POWERED BY ARTIFICIAL INTELLIGENCE, TO ANALYZE PRICE MIGRATION DATA FOR ONCOLOGY PRODUCTS

    Oct 1, 2018, 00:00

  • PSY188 - USE OF MANAGED ENTRY AGREEMENTS IN INFLAMMATORY DISORDERS AMONG KEY HEALTH TECHNOLOGY ASSESSMENT AGENCIES

    Oct 1, 2018, 00:00

  • PDB76 - COST-EFFECTIVENESS ANALYSIS OF EMPAGLIFLOZIN IN COMPARISON TO LIRAGLUTIDE BASED ON CARDIOVASCULAR OUTCOME TRIALS

    Oct 1, 2018, 00:00

  • PHP141 - THE PRIVATE HEALTHCARE MARKET IN BRAZIL- A REVIEW OF 18 YEARS OF PROGRESS

    Oct 1, 2018, 00:00

  • PMD118 - SEROLOGY TESTING IN SCHOOL-AGED CHILDREN WITH ASTHMA, IN THE UK, COULD LEAD TO SUBSTANTIAL COST SAVINGS FOR THE NHS- A POPULATION-BASED SIMULATION STUDY

    Oct 1, 2018, 00:00

  • PMD24 - ASSOCIATION BETWEEN IOL DESIGN AND INCIDENCE OF PCO AND ND-YAG CAPSULOTOMY- A RETROSPECTIVE REAL WORLD EVIDENCE STUDY IN THE UK

    Oct 1, 2018, 00:00

  • PCN156 - PHARMACOECONOMICS OF NIMOTUZUMAB IN PATIENTS WITH HEAD AND NECK CANCER IN CUBA

    Oct 1, 2018, 00:00

  • PMD54 - DRUG-COATED BALLOON THERAPY FOR TREATMENT OF CRITICAL LIMB ISCHEMIA IN FEMOROPOPLITEAL ARTERY DISEASE- ECONOMIC ANALYSIS FOR THE NETHERLANDS

    Oct 1, 2018, 00:00

  • PCV34 - A REVIEW ASSESSING THE INCIDENCE AND PREVALENCE OF CHRONIC HEART FAILURE WITH PRESERVED EJECTION FRACTION

    Oct 1, 2018, 00:00

  • PCP33 - COULD THE US ADMINISTRATION IMPOSE DRUG PRICE RAISES IN THE EUROPEAN UNION (EU)?

    Oct 1, 2018, 00:00

  • PSY216 - THE RELATIONSHIP BETWEEN HEALTH-RELATED QUALITY OF LIFE AND CLINICAL VERSUS SELF-REPORTED BODY MASS INDEX

    Oct 1, 2018, 00:00

  • PMS19 - A BUDGET IMPACT ANALYSIS OF INTRODUCING A FORCED TREATMENT PATHWAY USING THE LOWEST PRICED ANTI-TUMOR NECROSIS FACTOR AGENT FOR RHEUMATOID ARTHRITIS AND ANKYLOSING SPONDYLITIS IN THE PHILIPPINES

    Oct 1, 2018, 00:00

  • PMD104 - COST-EFFECTIVENESS AND COST-UTILITY ANALYSIS OF TREATING DIABETIC FOOT ULCERS WITH URGOSTART COMPARED TO A NEUTRAL DRESSING.

    Oct 1, 2018, 00:00

  • PMD124 - CLINICAL, PATIENT-REPORTED OUTCOME MEASURES (PROMS) AND ECONOMIC OUTCOMES ASSOCIATED WITH ENHANCED RECOVERY PROGRAMS IN BARIATRIC SURGERY IN EUROPE, THE MIDDLE EAST AND AFRICA- A SYSTEMATIC LITERATURE REVIEW

    Oct 1, 2018, 00:00

  • PDB45 - COSTS OF PREVENTION, MONITORING AND TREATMENT OF IODINE DEFICIENCY DISORDERS IN GERMANY

    Oct 1, 2018, 00:00

  • PHP276 - A REVIEW OF THE IMPACT OF INTEGRATED SCIENTIFIC ADVICE FOR THE OPTIMISATION OF EVIDENCE GENERATION FOR HTA APPRAISALS

    Oct 1, 2018, 00:00

  • PSY20 - REAL WORLD TREATMENT PERSISTANCE OF GOLIMUMAB IN THE MANAGEMENT OF IMMUNE-MEDIATED RHEUMATIC DISEASES (IMRDS) IN EUROPE- A SYSTEMATIC LITERATURE REVIEW (SLR)

    Oct 1, 2018, 00:00

  • PHP354 - THE IMPACT OF DATA PRIVACY REGULATIONS ON DRUG UTILIZATION DATA SHARING FOR INNOVATIVE PRICING ARRANGEMENTS

    Oct 1, 2018, 00:00

  • PSS55 - COMPARATIVE EFFECTIVENESS OF INTEGRATED LOCAL TREATMENTS OF GENERALIZED PERIODONTITIS AND CHRONIC GINGIVITIS

    Oct 1, 2018, 00:00

  • PIN16 - BUDGET IMPACT ANALYSIS OF INTRODUCING A READY-TO-USE, FULLY-LIQUID, PAEDIATRIC, HEXAVALENT VACCINE FOR CHILDHOOD IMMUNISATION IN THE UNITED KINGDOM

    Oct 1, 2018, 00:00

  • PSY39 - QUANTIFYING WORLDWIDE EVIDENCE TO ESTIMATE THE RISK OF TRANSMITTING CREUTZFELDT-JAKOB DISEASE VIA SURGICAL PROCEDURES

    Oct 1, 2018, 00:00

  • PRM132 - MODELING MULTIPLE CARDIOVASCULAR EVENT HISTORY USING NESTED PARTITIONED SURVIVAL MODELS

    Oct 1, 2018, 00:00

  • PCV5 - REAL-WORLD LDL-C CHANGES EXPERIENCED WITH LOMITAPIDE MODELLED TO POTENTIALLY INCREASE LIFE-EXPECTANCY IN HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HOFH)

    Oct 1, 2018, 00:00

  • PHP227 - THE CURRENT REIMBURSEMENT LANDSCAPE FOR DIGITAL HEALTH IN THE UK- HOW FAR ARE WE FROM A CENTRALISED, NATIONAL SYSTEM?

    Oct 1, 2018, 00:00

  • PMD63 - POTENTIAL LONG-TERM SAVINGS RESULTED FROM THE INTRODUCTION OF INVASIVE EEG MONITORING AS A PREOPERATIVE DIAGNOSTIC PROCEDURE IN EPILEPSY SURGERY IN HUNGARY

    Oct 1, 2018, 00:00

  • PDB128 - COMPARISON OF PATIENT ACTIVATION LEVELS ACROSS VARIOUS CONDITIONS IN THE US AND EU5

    Oct 1, 2018, 00:00

  • PRM66 - AN EXPLORATION OF THE METHODOLOGY FOR CONSIDERING TREATMENT DURATION IN BUDGET IMPACT ANALYSES IN ONCOLOGY- A CASE STUDY IN SECOND LINE ADVANCED RENAL CELL CARCINOMA

    Oct 1, 2018, 00:00

  • PND53 - MODEL-BASED ECONOMIC EVALUATIONS OF TREATMENTS FOR PARKINSON’S DISEASE- A SYSTEMATIC LITERATURE REVIEW

    Oct 1, 2018, 00:00

  • PDB20 - PERSISTENCE TO LIRAGLUTIDE THERAPY IS ASSOCIATED WITH BETTER GLYCEMIC AND WEIGHT CONTROL IN PATIENTS WITH TYPE 2 DIABETES

    Oct 1, 2018, 00:00

  • PIH53 - COMPARISON OF THE EQ-5D-5L AND THE EQ-5D-3L USING INDIVIDUAL PATIENT DATA FROM REFORM TRIAL

    Oct 1, 2018, 00:00

  • PHP200 - A REVIEW OF ACHIEVEMENTS AND CHALLENGES OF IRAN’S HEALTH TRANSFORMATION PLAN

    Oct 1, 2018, 00:00

  • PMU43 - THE COST OF INFORMAL CARE IN HUNGARY- A POOLED ANALYSIS OF 14 CROSS-SECTIONAL STUDIES

    Oct 1, 2018, 00:00

  • PCN92 - THE EVALUATION OF THE ECONOMIC EFFICIENCY OF LENVATINIB IN COMBINATION WITH EVEROLIMUS IN RUSSIAN PATIENTS WITH DISSEMINATED RENAL CELL CARCINOMA

    Oct 1, 2018, 00:00

  • PCN384 - HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH ADVANCED (STAGE II-IV) OVARIAN CANCER RESISTANT OR REFRACTORY TO FRONTLINE PLATINUM-BASED THERAPY

    Oct 1, 2018, 00:00

  • PHP183 - PRICE DIFFERENCE OF MEDICINES DISPENSED IN COMMUNITY PHARMACIES AND IN THE HOSPITAL SECTOR - AN ANALYSIS ON THE MEDICINES FINANCED ON THE BASIS OF HOSPITAL SERVICE TARIFFS

    Oct 1, 2018, 00:00

  • PHP140 - CURRENT CHALLENGES AND POTENTIAL SOLUTION FOR PRICING REGULATORY AND REIMBURSEMENT FRAMEWORK OF INNOVATIVE DRUGS IN EGYPT

    Oct 1, 2018, 00:00

  • PHP292 - ROADMAP FOR IMPLEMENTATION OF HEALTH TECHNOLOGY ASSESSMENT IN ROMANIA

    Oct 1, 2018, 00:00

  • PND99 - CYSTIC FIBROSIS THERAPIES - KEY DRIVERS BEHIND DIFFERING HTA DECISIONS

    Oct 1, 2018, 00:00

  • PHP106 - IMPACT OF ACCESS RESTRICTION ON USE OF SHORT-ACTING PRESCRIPTION OPIOIDS IN A US HEALTH PLAN

    Oct 1, 2018, 00:00

  • PCV33 - THE RATE OF CARDIOVASCULAR EVENTS IN DIABETIC PATIENTS IN COLOMBIA

    Oct 1, 2018, 00:00

  • PCN128 - COSTS OF HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) IN PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA (ALL), DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) AND FOLLICULAR LYMPHOMA (FL) – A RETROSPECTIVE ANALYSIS OF JAPANESE CLAIMS DATA

    Oct 1, 2018, 00:00

  • PDB3 - THE IMPACT OF GLYCATED HEMOGLOBIN CONTROL ON MORBIDITY AND SURVIVAL AMONG PATIENTS WITH TYPE 2 DIABETES MELLITUS

    Oct 1, 2018, 00:00

  • PMD179 - PATIENTS’ USABILITY OF SIX MOST USED DRY-POWDER INHALERS IN ASTHMA AND COPD

    Oct 1, 2018, 00:00

  • PIN112 - HEALTH TECHNOLOGY ASSESSMENT OF THE AVAILABLE NRTI BACKBONES IN ITALY

    Oct 1, 2018, 00:00

  • PSY142 - THE ACCESS (TIMING AND AVAILABILITY) OF ORPHAN MEDICINE USE AND ITS DETERMINANTS AMONG OECD COUNTRIES FROM 2006 THROUGH 2016

    Oct 1, 2018, 00:00

  • PHP225 - ASSESSMENT OF THE UNIT COSTS IN IMAGING ACTS- THE EXAMPLE OF MRI AND CT-SCAN ACTS IN FRANCE

    Oct 1, 2018, 00:00

  • PRM150 - TECHNOLOGY DIFFUSION IN HEALTHCARE- INSIGHTS FROM AN AGENT-BASED SIMULATION

    Oct 1, 2018, 00:00

  • PSY151 - REAL-WORLD IMPACT OF HIGH CONCENTRATION NON-AVIAN HIGH MOLECULAR WEIGHT HYALURONAN ON UTILIZATION PATTERNS OF PAIN MEDICATIONS AMONG PATIENTS WITH OSTEOARTHRITIS OF KNEE

    Oct 1, 2018, 00:00

  • PMD130 - HEALTH TECHNOLOGY ASSESSMENT (HTA) OF MEDICAL DEVICES IN EUROPE- THE CALM BEFORE THE STORM OR ALREADY WIND FORCE 8?

    Oct 1, 2018, 00:00

  • PHP212 - A DECADE OF PUBLIC-PRIVATE PARTNERSHIPS (PDPS) IN BRAZIL- AN EXPLORATORY ANALYSIS OF PROGRESS AND CHALLENGES

    Oct 1, 2018, 00:00

  • PCN93 - ECONOMIC MODELING FOR THE US OF INTRAVENOUS VS SUBCUTANEOUS RITUXIMAB IN NON-HODGKIN’S LYMPHOMA TREATED WITH R-CHOP

    Oct 1, 2018, 00:00

  • PND93 - THE IMPACT OF MYASTHENIA GRAVIS (MG) ON HEALTHCARE RESOURCE UTILIZATION- EMPIRICAL EVIDENCE FROM A US REGISTRY SAMPLE

    Oct 1, 2018, 00:00

  • PSY185 - ALTERNATIVE METHODOLOGIES IMPLEMENTED BY HTA AGENCIES FOR ORPHAN DRUGS- A SCOPING REVIEW

    Oct 1, 2018, 00:00

  • PMU34 - PRICE ANALYSIS OF VACCIENS MARKETED IN THE GULF COOPERATION COUNCIL COUNTRIES- A CROSS-SECTIONAL STUDY

    Oct 1, 2018, 00:00

  • PDB27 - CLINICAL INERTIA IN RELATION TO BARRIERS TO PROGRESSION TO INJECTABLE THERAPY IN TYPE 2 DIABETES- A SYSTEMATIC LITERATURE REVIEW

    Oct 1, 2018, 00:00

  • PCN211 - PATIENT CASE-MIX OF A TERTIARY CLINICAL CENTRE WITH PATIENTS DIAGNOSED WITH MALIGNANT MELANOMA BETWEEN 2012-2015

    Oct 1, 2018, 00:00

  • PIH24 - MODELLED EFFECTS OF A PEDIATRIC TRIPLE-CHAMBER-BAG (3CB) SYSTEM ON PAYER COSTS AND CLINICAL OUTCOMES IN PRE-TERM NEONATES ACROSS FRANCE, GERMANY AND ITALY

    Oct 1, 2018, 00:00

  • PCN240 - ALL-COMERS VS. BIOMARKER BASED PATIENT SELECTION FOR BIOTHERAPIES IN ONCOLOGY- IMPACT ON DRUG DEVELOPMENT AND MARKET ACCESS

    Oct 1, 2018, 00:00

  • PCN123 - EVALUATION OF DRUG THERAPY COSTS FOR PATIENTS WITH BREAST CANCER, MELANOMA AND RENAL CELL CARCINOMA IN MOSCOW IN 2016-2017

    Oct 1, 2018, 00:00

  • PHP213 - A RETROSPECTIVE REVIEW OF REIMBURSEMENT DECISIONS BY THE HAUTE AUTORITÉ DE SANTÉ IN 2017 - UNDERLYING RATIONALE FOR MEDICINAL PRODUCTS WITH INSUFFICIENT ACTUAL MEDICAL BENEFIT

    Oct 1, 2018, 00:00

  • PRM219 - A NOVEL MEASURE OF DRUG BENEFIT-RISK ASSESSMENT BASED ON SCALE LOSS SCORE (SLOS)

    Oct 1, 2018, 00:00

  • PMD46 - COST-COST MODEL FOR RULING OUT CORONARY ARTERY DISEASE IN SYMPTOMATIC PATIENTS WITH ULTRA-SENSITIVE PHONOCARDIOGRAPHY IN THE GERMAN AMBULATORY SECTOR

    Oct 1, 2018, 00:00

  • PMD173 - TREATMENT DIFFERENCES IN CHILDREN BURN CARE IN GERMANY BETWEEN BURN CENTERS AND NON-CENTERS

    Oct 1, 2018, 00:00

  • PRM92 - INITIAL DEVELOPMENT OF INTELLIGENCE ON HEALTH CARE DATA IN BRASIL- FACING THE OBSTACLES

    Oct 1, 2018, 00:00

  • QL4 - ASSESSMENT OF QUALITY OF LIFE IN PATIENTS WITH METASTATIC MELANOMA IN REAL CLINICAL PRACTICE IN FRANCE

    Oct 1, 2018, 00:00

  • PSY130 - THE RELATIONSHIP BETWEEN DISEASE TYPE AND CONDITIONAL OR EXCEPTIONAL APPROVAL BY EMA FOR ORPHAN DRUGS IN 2017

    Oct 1, 2018, 00:00

  • PCN344 - NUTRITION BEHAVIOUR OF PATIENTS WITH BREAST CANCER

    Oct 1, 2018, 00:00

  • PND19 - INCIDENCE OF EPILEPSY AFTER STROKES AND REAL-WORLD ANTIEPILEPTIC DRUG TREATMENT

    Oct 1, 2018, 00:00

  • PMS8 - REAL-WORLD USE OF PROPHYLACTIC ANTIBIOTICS IN TOTAL KNEE ARTHROPLASTY

    Oct 1, 2018, 00:00

  • PDB70 - ECONOMIC EVALUATION OF THE USE OF RECOMBINANT HUMAN EPIDERMAL GROWTH FACTOR (HEBERPROT-P®) AS AN ADJUVANT OF CONVENTIONAL THERAPY FOR THE TREATMENT OF DIABETIC FOOT ULCER

    Oct 1, 2018, 00:00

  • PCN99 - EVALUATING THE INCREASING STRAIN OF IMMUNOTHERAPIES (PD-1/PD-L1) ON PUBLIC HEALTHCARE SYSTEMS IN T5 + US

    Oct 1, 2018, 00:00

  • PRM76 - WHAT PHYSICIANS WANT- SEARCH AND EVIDENCE SOURCE TRENDS IN THE TRIP HEALTHCARE DATABASE

    Oct 1, 2018, 00:00

  • PCV115 - QUALITY OF INR CONTROL AND SWITCHING TO DOAC BETWEEN WOMEN AND MEN WITH ATRIAL FIBRILLATION TREATED WITH VITAMIN K ANTAGONISTS IN SPAIN. A POPULATION-BASED, REAL-WORLD STUDY.

    Oct 1, 2018, 00:00

  • PRS73 - THE BUDGET IMPACT OF NICOTINIC SUBSTITUTE REIMBURSEMENT

    Oct 1, 2018, 00:00

  • PSY81 - DIRECT COSTS ASSOCIATED WITH THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) RELAPSED OR REFRACTORY IN ARGENTINA

    Oct 1, 2018, 00:00

  • PHP84 - INVESTIGATING USAGE OF REFERENCE COUNTRIES FOR PRICING AND HEALTH TECHNOLOGY ASSESSMENT OF MEDICINES IN CEE COUNTRIES

    Oct 1, 2018, 00:00

  • PCV58 - HEALTH INSURANCE TREATMENT COST OF SECONDARY HYPERTENSION IN HUNGARY- A NATIONWIDE COST OF ILLNESS STUDY

    Oct 1, 2018, 00:00

  • PCV79 - REAL-WORLD COST-EFFECTIVENESS OF RIVAROXABAN COMPARED WITH VITAMIN K ANTAGONISTS IN THE CONTEXT OF STROKE PREVENTION IN ATRIAL FIBRILLATION IN FRANCE

    Oct 1, 2018, 00:00

  • PMH18 - MARKOV MODEL FOR PREDICTING THE RISK OF DEVELOPING DEMENTIA IN ELDERLY ADULTS

    Oct 1, 2018, 00:00

  • PCN102 - EXTRA-COST OF BRAIN METASTASES IN PATIENTS WITH NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC) - A FRENCH NATIONAL HOSPITAL DATABASE ANALYSIS

    Oct 1, 2018, 00:00

  • PRM184 - ANALYSIS OF UTILITY VALUES USED IN NICE APPRAISALS OF HIGHLY SPECIALISED TECHNOLOGIES

    Oct 1, 2018, 00:00

  • PCN307 - APPLYING MULTI-CRITERIA DECISION ANALYSIS (MCDA) AS AN EVIDENCE BASED HEALTH TECHNOLOGY ASSESSMENT IN HEALTH CARE DECISION MAKING IN EGYPT

    Oct 1, 2018, 00:00

  • PMU15 - ANALYSIS OF THE METHODOLOGICAL OBJECTIONS REGARDING INDIRECT TREATMENT COMPARISON SUBMITTED TO THE HAUTE AUTORITÉ DE SANTÉ (HAS)

    Oct 1, 2018, 00:00

  • PMS11 - ESTIMATING THE PREVALENCE, AND DESCRIBING THE MEDICAL HISTORY AND TREATMENT PATTERNS OF PATIENTS WITH NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS IN GERMANY – AN APPROACH USING A CLAIMS DATABASE

    Oct 1, 2018, 00:00

  • PMD11 - STAGING INVESTIGATION STRATEGIES FOR DISTANT METASTASES DETECTION IN WOMEN WITH BREAST CANCER- A SYSTEMATIC REVIEW AND META-ANALYSIS

    Oct 1, 2018, 00:00

  • PCN235 - COMBINATION ONCOLOGY THERAPIES IN THE EU5- NAVIGATING THE ROAD TO REIMBURSEMENT AND OPTIMIZING UPTAKE IN MALIGNANT MELANOMA

    Oct 1, 2018, 00:00

  • PMD100 - ECONOMIC EVALUATION OF PROTHROMBIN TIME TEST STRIPS (COAGUCHEK PRO II)

    Oct 1, 2018, 00:00

  • PGI41 - CLINICAL CHARACTERISTICS OF BIOLOGIC TREATED CROHN’S DISEASE PATIENTS WITH AND WITHOUT PRIOR SURGERY IN EUROPEAN UNION

    Oct 1, 2018, 00:00

  • PSY157 - EMERGING RHEUMATOID ARTHRITIS AND PSORIASIS BIOLOGICS- HOW TO THRIVE IN THE FACE OF BIOSIMILAR COMPETITION?

    Oct 1, 2018, 00:00

  • PSS73 - IMPACT OF CENEGERMIN ON THE QUALITY OF LIFE IN NEUROTROPHIC KERATOPATHY

    Oct 1, 2018, 00:00

  • PGI7 - ROBUST ESTIMATES CONCERNING THE HCV ELIMINATION STRATEGY IN GREECE. COMBINING THE RESULTS FROM TWO DIFFERENT MATHEMATICAL MODELS

    Oct 1, 2018, 00:00

  • PMS98 - EFFECTIVENESS OF FALL PREVENTION PROGRAM IN PATIENTS WITH OSTEOPOROSIS

    Oct 1, 2018, 00:00

  • PMD29 - BUDGET IMPACT ANALYIS OF MECHANICHAL THROMBECTOMY IN THE TREATMENT OF ACUTE ISCHEMUC STROKE

    Oct 1, 2018, 00:00

  • PIN19 - A COST COMPARISON OF TREATING CHRONIC HEPATITIS C PATIENTS WITH SOFOSBUVIR-BASED REGIMENS

    Oct 1, 2018, 00:00

  • PCV4 - NON CARDIOVASCULAR COMORBITY AND PROGNOSIS OF CONGESTIVE HEART FAILURE

    Oct 1, 2018, 00:00

  • PRS56 - COST-EFFECTIVENESS OF AMBULATORY OXYGEN IN IMPROVING QUALITY OF LIFE IN FIBROTIC LUNG DISEASE- A TALE OF TWO OUTCOMES

    Oct 1, 2018, 00:00

  • PIN110 - COMPARISON OF DRUG ASSESSMENT REPORTS PUBLISHED BY FRENCH (HAS-CEESP) AND UK (NICE) HTAS- FOCUS ON HEPATITIS C

    Oct 1, 2018, 00:00

  • PHP76 - ANALYSIS OF APPROVAL TIMING FOR 89 NEW DRUGS IN ITALY FROM JANUARY 2015 TO MAY 2018

    Oct 1, 2018, 00:00

  • PDB52 - ANNUAL COST OF ACUTE MYOCARDIAL INFARCTION IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN TURKEY

    Oct 1, 2018, 00:00

  • PHP324 - NICE- A MULTIPROGRAM HTA ORGANIZATION TO SUIT ALL?

    Oct 1, 2018, 00:00

  • MO2 - MODELLING OVERALL SURVIVAL IN IMMUNOTHERAPY USING PARAMETRIC TECHNIQUES- AVELUMAB IN PREVIOUSLY TREATED METASTATIC MERKEL CELL CARCINOMA

    Oct 1, 2018, 00:00

  • PMS62 - COST-EFFECTIVENESS OF REDUCING ARTHRITIS FATIGUE BY CLINICAL TEAMS (RAFT) USING COGNITIVE–BEHAVIOURAL APPROACHES- A RANDOMISED CONTROLLED TRIAL

    Oct 1, 2018, 00:00

  • PCN84 - TOTAL COST OF CARE AND BUDGET IMPACT FOR PATIENTS WITH CLL TREATED WITH VENETOCLAX

    Oct 1, 2018, 00:00

  • PRM29 - COMPARING OPTHALMOLOGY TREATMENTS VIA THE INTEGRATION OF IPD AND AGGREGATE-LEVEL DATA- WHICH MATCHING ADJUSTED INDIRECT COMPARISON (MAIC) APPROACH IS BEST?

    Oct 1, 2018, 00:00

  • PCN107 - BURDEN AND COSTS OF ACUTE MYELOID LEUKAEMIA IN PORTUGAL

    Oct 1, 2018, 00:00

  • PCV16 - A SYSTEMATIC REVIEW ON THE EFFICACY OF PHARMACOLOGICAL TREATMENTS IN PATIENTS WITH HEART FAILURE (HF) WITH PRESERVED EJECTION FRACTION (HFPEF)

    Oct 1, 2018, 00:00

  • PCV53 - IS EDOXABAN MORE COST-EFFECTIVE THAN WARFARIN IN PREVENTION OF STROKE AND DEEP VEIN THROMBOSIS?

    Oct 1, 2018, 00:00

  • PCN147 - COST-EFFECTIVENESS SIMULATION AND ANALYSIS OF COLORECTAL CANCER SCREENING IN SHANGHAI POPULATION, CHINA- COMPARISON BETWEEN URBAN AND RURAL RESIDENTS

    Oct 1, 2018, 00:00

  • PRM212 - PATIENT EXPERIENCE WITH PLATINUM-RESISTANT OR PLATINUM-REFRACTORY OVARIAN CANCER

    Oct 1, 2018, 00:00

  • PRM134 - USING ADJUSTED INDIRECT COMPARISON IN HTA TO OVERCOME SHORT FOLLOW-UP TIME IN REGULATORY RANDOMIZED CONTROLED CLINICAL TRIALS- RIBOCICLIB AS FIRST-LINE THERAPY FOR HR-POSITIVE, ADVANCED BREAST CANCER

    Oct 1, 2018, 00:00

  • PSS13 - BUDGET IMPACT ANALYSIS OF APREMILAST IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS IN GREECE

    Oct 1, 2018, 00:00

  • PDB96 - APPLYING MCDA FRAMEWORK IN PHARMACEUTICAL POLICY DECISION MAKING- A PILOT STUDY IN DIABETES MELLITUS TYPE 2

    Oct 1, 2018, 00:00

  • PCN316 - RELATIONSHIP BETWEEN TWO CANCER CLINICAL BENEFIT FRAMEWORKS AND HEALTH TECHNOLOGY DECISIONS IN THREE EUROPEAN COUNTRIES

    Oct 1, 2018, 00:00

  • PMS2 - RETROSPECTIVE STUDY TO EVALUATE OSTEOARTHRITIS POPULATION IN GERMANY AND IDENTIFY INFLUENTIAL FACTORS IN FAST, MEDIUM AND SLOW PROGRESSING PATIENTS

    Oct 1, 2018, 00:00

  • PHP38 - ENZYME REPLACEMENT THERAPIES WITHIN THE GERMAN HTA (AMNOG) PROCESS

    Oct 1, 2018, 00:00

  • PCN189 - ANALYSIS COST / UTILITY OF THE THERAPEUTIC THERAPY TREATMENT OF LUNG CANCER IN A UNIVERSITY HOSPITAL OF SPAIN

    Oct 1, 2018, 00:00

  • PCP44 - IMPLICATIONS OF GENOME-DRIVEN ONCOLOGY ON EVIDENCE REQUIREMENTS FOR HEALTH TECHNOLOGY ASSESSMENT

    Oct 1, 2018, 00:00

  • PSS20 - ECONOMIC BURDEN OF PSORIASIS (PSO) IN TURKEY

    Oct 1, 2018, 00:00

  • PRM191 - LONGITUDINAL CONSTRUCT VALIDITY OF THE HEMOPHILIA CAREGIVER IMPACT MEASURE

    Oct 1, 2018, 00:00

  • PCN1 - REAL-WORLD EFFECTIVENESS AND TOLERABILITY OF SMALL-CELL LUNG CANCER (SCLC) TREATMENTS- A SYSTEMATIC LITERATURE REVIEW (SLR)

    Oct 1, 2018, 00:00

  • PCN56 - TREATMENT EFFECT MODIFICATION (EM) OF ANTICANCER THERAPIES IN FIRST-LINE ADVANCED NON-SMALL CELL LUNG CANCER (ANSCLC)- A SYSTEMATIC ASSESSMENT OF TRIAL DATA

    Oct 1, 2018, 00:00

  • PGI51 - PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS (NASH) REPORT HIGHER ECONOMIC BURDEN THAN CONTROLS- RESULTS FROM THE EU5 NATIONAL HEALTH AND WELLNESS SURVEY

    Oct 1, 2018, 00:00

  • PSY171 - EXPECTED AND ACTUAL REIMBURSEMENT BASED ON CLINICAL PRACTICE GUIDELINE RECOMMENDATIONS IN TURKEY

    Oct 1, 2018, 00:00

  • PP4 - ONE SIZE DOES NOT FIT ALL- HETEROGENEOUS PATIENT PREFERENCES AND TRADEOFFS FOR ANTIRETROVIRAL THERAPY - RESULTS OF A DISCRETE CHOICE EXPERIMENT

    Oct 1, 2018, 00:00

  • PRM70 - NON-SMALL CELL LUNG CANCER MARKET ANALYSIS FOR TARGETED THERAPIES IN TURKEY

    Oct 1, 2018, 00:00

  • PMH54 - PATTERNS OF LONG-TERM CUSTODIAL CARE IN PARKINSON DISEASE PSYCHOSIS

    Oct 1, 2018, 00:00

  • PDB14 - MOBILE APPS FOR MEDICATION ADHERENCE IN DIABETES

    Oct 1, 2018, 00:00

  • PCP47 - TAMING THE TORNADO CHART- SIMPLIFYING ONE-WAY SENSITIVITY ANALYSES FOR LARGE-SCALE MULTI-PARAMETER MODELS

    Oct 1, 2018, 00:00

  • PCV152 - TREATMENT BURDEN ASSOCIATED WITH DIFFERENT ANTICOAGULATION STRATEGIES OF ATRIAL FIBRILLATION PATIENTS- AN OBSERVATIONAL STUDY IN GERMANY, SWEDEN AND SWITZERLAND BASED ON THE ANTI-CLOT TREATMENT SCALE

    Oct 1, 2018, 00:00

  • PCN141 - COST-EFFECTIVENESS ANALYSIS OF OBINUTUZUMAB FOR THE TREATMENT OF PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED FOLLICULAR LYMPHOMA IN GREECE

    Oct 1, 2018, 00:00

  • PSY31 - COMPARISON OF THE ESTIMATED PREVALENCE OF DIAGNOSED HOMOCYSTINURIA AND PHENYLKETONURIA IN THE UNITED STATES

    Oct 1, 2018, 00:00

  • PSY107 - COST-EFFECTIVENESS OF BUDESONIDE IN MICROSCOPIC COLITIS PATIENTS IN THE CZECH REPUBLIC

    Oct 1, 2018, 00:00

  • PCV108 - PRESCRIBING CHOICE AND THE COST OF ANTICOAGULATION IN ATRIAL FIBRILLATION- A REAL WORLD STUDY COMPARING HEALTHCARE EXPENDITURE WITH WARFARIN AND APIXABAN

    Oct 1, 2018, 00:00

  • RM4 - EXPLORING TIME-DEPENDENT VARIATION OF PATIENT-REPORTED OUTCOME SCORES ACROSS DIFFERENT TIME-POINTS FOR PATIENTS WITH MULTIPLE CONDITIONS- A MIXED METHODS LONGITUDINAL STUDY

    Oct 1, 2018, 00:00

  • PMD174 - IMPACT OF MEDICAL DEVICE REGULATION ON FUTURE HTA’S AND REIMBURSEMENT DECISIONS IN GERMANY, FRANCE AND SWITZERLAND – WHAT IS BLOOMING HERE?

    Oct 1, 2018, 00:00

  • PHP249 - ARE TRADITIONAL MANAGED ENTRY AGREEMENTS SUITABLE FOR POTENTIALLY, CURATIVE GENE/CELL THERAPIES?

    Oct 1, 2018, 00:00

  • PCN89 - COST –EFFECTIVENESS ANALYSIS OF PERTUZUMAB AS FIRST LINE NEOADJUVANT TREATMENT OPTION FOR PATIENTS HER2 + BREAST CANCER IN REPUBLIC OF MACEDONIA

    Oct 1, 2018, 00:00

  • PHP1 - EXPECTED DEMAND FOR HEALTH SERVICES FROM A VOLUNTARY INSURER

    Oct 1, 2018, 00:00

  • PHP216 - HOW RESPONSIVE IS INDUSTRY TO VALUE BASED PROCUREMENT (VBP)?

    Oct 1, 2018, 00:00

  • PHP174 - ARE FIXED THERAPEUTIC-LEVEL SPENDING CAPS ADVISABLE FOR THE GREEK OUTPATIENT MARKET? METHODOLOGICAL ISSUES AND HEALTH POLICY PROPOSALS

    Oct 1, 2018, 00:00

  • PRM33 - HUMAN CAPITAL VS. FRICTION COST APPROACH – DIFFERENCES IN THE PRESENCE OF DEATH AND LONG-TERM CONSEQUENCES

    Oct 1, 2018, 00:00

  • PSS7 - QUALITY OF LIFE IMPROVEMENTS IN PSORIASIS WITH SECUKINUMAB IN A DIFFICULT TO TREAT POPULATION OF ANTI-TNF ALPHA FAILURE PATIENTS FROM THE UK AND REPUBLIC OF IRELAND

    Oct 1, 2018, 00:00

  • PMD170 - A RESEARCH ON HOSPITAL BASED-HEALTH TECHNOLOGY ASSESSMENT MODELS OF ACQUISITION OF MEDICAL DEVICES IN HOSPITALS- THE CASE OF TURKEY

    Oct 1, 2018, 00:00

  • PCN105 - ECONOMIC BURDEN OF RECURRENT AND/OR METASTATIC SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK IN FRANCE

    Oct 1, 2018, 00:00

  • PHP74 - A REVIEW OF THE INFLUENCE OF INTERNATIONAL REFERENCE PRICING (IRP) ON LAUNCH SEQUENCING IN EUROPE

    Oct 1, 2018, 00:00

  • PRM18 - REAL-WORLD DATA (RWD) COLLECTION ALONGSIDE EARLY ACCESS TO MEDICINES SCHEMES (EAMS) - NIVOLUMAB IN GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA (GC/GEJ) AFTER TWO OR MORE PRIOR THERAPIES

    Oct 1, 2018, 00:00

  • PCN390 - METASTATIC COLORECTAL CANCER (MCRC) - LITERATURE REVIEW ON QUALITY OF LIFE INSTRUMENTS

    Oct 1, 2018, 00:00

  • PMH17 - PREDICTING RECURRENCE OF DEPRESSION USING LIFELOG DATA- A PANEL VAR APPROACH

    Oct 1, 2018, 00:00

  • PMU53 - HOSPITAL COSTS OF SPINAL LUMBAR FUSION SURGERIES WITH NEUROMONITORING

    Oct 1, 2018, 00:00

  • PCN258 - HEALTHCARE RESOURCE UTILISATION (HCRU) AMONG PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC) IN SWEDEN- THE SCAN-LEAF STUDY

    Oct 1, 2018, 00:00

  • PCP4 - DEVELOMENT OF A QUALITY MANAGEMENT SYSTEM FOR EUNETHTA AND THE PERMANENT EUROPEAN COLLABORATION ON HTA

    Oct 1, 2018, 00:00

  • PIH29 - DEVELOPMENT OF A DECISION AID PROTOTYPE FOR PARENTS CONSIDERING TUBE FEEDING FOR THEIR CHILDREN

    Oct 1, 2018, 00:00

  • PHP323 - ESTABLISHING AN ALIGNED VIEW OF MODERN, FORWARD-LOOKING HTA PROCESS

    Oct 1, 2018, 00:00

  • PDB47 - THE ASSOCIATION BETWEEN RENAL FUNCTION AND HEALTHCARE COSTS IN US PATIENTS WITH TYPE 2 DIABETES

    Oct 1, 2018, 00:00

  • PMD68 - A COST-CONSEQUENCE ANALYSIS OF ANACONDA VERSUS PROPOFOL AND MIDAZOLAM IN THE LONG-TERM SEDATION OF CRITICALLY-ILL SURGICAL PATIENTS FROM THE UK NHS PERSPECTIVE

    Oct 1, 2018, 00:00

  • PCN275 - HOW DO HTA DECISIONS FOR NEW DISEASE CONDITIONS IMPACT TIME TO PRICE CHANGES?

    Oct 1, 2018, 00:00

  • PMS97 - THE EFFECT OF NEUROMUSCULAR AND NEUROMUSCULAR-CORE TRAINING ON INJURY PREVENTION

    Oct 1, 2018, 00:00

  • PRM6 - INCREASED RISK OF CUTANEOUS ADVERSE DRUG REACTION AMONG OLDER ADULTS EXPOSED TO POLYPHARMACY

    Oct 1, 2018, 00:00

  • PCN135 - DOES PATIENT SELECTION CRITERIA TRANSLATE INTO COST SAVINGS IN PATIENTS WITH ADVANCED/METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) AFTER CHEMOTHERAPY FAILURE IN SPAIN?

    Oct 1, 2018, 00:00

  • PRM98 - FACTORS ASSOCIATED WITH THE INCIDENCE OF ONCOLOGY DRUGS SHORTAGES IN THE UNITED STATES (2001-2017)

    Oct 1, 2018, 00:00

  • PHP77 - EFFECT OF NEW INDICATIONS ON THE PRICE DEVELOPMENT OF NEW MEDICINAL PRODUCTS IN GERMANY

    Oct 1, 2018, 00:00

  • PDB74 - IDEGLIRA VERSUS IGLARLIXI FOR PATIENTS WITH INADEQUATELY CONTROLLED TYPE 2 DIABETES ON BASAL INSULIN- A LONG-TERM COST-EFFECTIVENESS ANALYSIS IN THE CZECH REPUBLIC

    Oct 1, 2018, 00:00

  • PCN229 - COMPARISON OF SICKNESS BENEFIT AND SICK LEAVE DURATION IN ONCOLOGY ACROSS COUNTRIES

    Oct 1, 2018, 00:00

  • PND67 - ARE NEW PREVENTIVE MIGRAINE DRUGS COST-EFFECTIVE FOR PATIENTS WITH CHRONIC AND EPISODIC MIGRAINE FOR WHOM OTHER PREVENTIVE MEDICATIONS HAD FAILED?

    Oct 1, 2018, 00:00

  • PMU56 - ECONOMIC EVALUATION OF POSACONAZOLE IN COMPARISON WITH LIPOSOMAL AMPHOTERICIN B IN THE TREATMENT OF MUCORMYCOSIS IN IRAN

    Oct 1, 2018, 00:00

  • PCN64 - REVIEW OF NICE HTA SUBMISSIONS INCLUDING METHODOLOGIES ADJUSTING FOR OVERALL SURVIVAL IN THE PRESENCE OF TREATMENT SWITCHING

    Oct 1, 2018, 00:00

  • PCV20 - NUMBER NEEDED TO TREAT FOR ORAL ANTI-COAGULANTS VERSUS VKA IN STROKE PREVENTION IN ATRIAL FIBRILLATION

    Oct 1, 2018, 00:00

  • PCN124 - DIRECT COST OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (AHSCT) FOR RELAPSED/REFRACTORY (RR) DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS FROM THE FRENCH HOSPITAL PERSPECTIVE

    Oct 1, 2018, 00:00

  • PRM241 - AN OUT-OF-SAMPLE METHOD TO QUANTIFY SYSTEMATIC ERROR IN UNANCHORED INDIRECT COMPARISONS

    Oct 1, 2018, 00:00

  • PCN70 - ASSESSING THE BUDGET IMPACT OF INCLUDING SUNITINIB FOR THE TREATMENT OF METASTATIC RENAL CELL CARCINOMA IN ARGENTINA

    Oct 1, 2018, 00:00

  • HT7 - A REVIEW OF EFFICIENCY OPINIONS OF FRENCH ‘HAUTE AUTORITE DE SANTE’ (HAS) IN THE ONCOLOGY FIELD

    Oct 1, 2018, 00:00

  • ND3 - META-ANALYSIS OF REAL-WORLD ADHERENCE AND PERSISTENCE OF MAINTENANCE ONCE- OR TWICE-DAILY ORAL DISEASE-MODIFYING DRUGS (DIMETHYL FUMARATE, FINGOLIMOD, AND TERIFLUNOMIDE) IN MULTIPLE SCLEROSIS

    Oct 1, 2018, 00:00

  • PSS59 - CLINICAL CHARACTERISTICS OF BIOLOGIC ELIGIBLE HIDRADENITIS SUPPURATIVA PATIENTS IN EU5

    Oct 1, 2018, 00:00

  • PCN96 - INITIAL THERAPY FOR ADVANCED PROSTATE CARCINOMA (PCA) WITH A GNRH AGONIST (GNRHA) AND ANTAGONISTS - A RETROSPECTIVE ANALYSIS OF PRESCRIPTION PATTERNS AND HOSPITAL COSTS BASED ON GERMAN GKV [GESETZLICHE KRANKENVERSICHERUNG (STATUTORY ...

    Oct 1, 2018, 00:00

  • PMD2 - STUDY OF STATINS EFFECTS ON COGNITIVE IMPAIRMENT AMONG OUTPATIENTS WITH TYPE 2 DIABETES MELLITUS

    Oct 1, 2018, 00:00

  • PIN44 - ECONOMIC EVALUATION OF 60+ YEARS ADULT VACCINATION STRATEGY USING PNEUMOCOCCAL POLYSACCHARIDE VACCINE IN SPAIN

    Oct 1, 2018, 00:00

  • PND111 - ELICITING PREFERENCES IN RELAPSING-REMITTING MULTIPLE SCLEROSIS – A BRAZILIAN STUDY USING A MULTICRITERIA DECISION ANALYSIS (MCDA) APPROACH

    Oct 1, 2018, 00:00

  • PSY148 - PRIMARY NON-ADHERENCE AMONG NEWLY DIAGNOSED RHEUMATOID ARTHRITIS PATIENTS

    Oct 1, 2018, 00:00

  • PND110 - GENE THERAPY PRODUCTS – MARKET ACCESS SITUATION IN EU AND IN SLOVAKIA

    Oct 1, 2018, 00:00

  • PSS33 - SECUKINUMAB AS FIRST BIOLOGIC TREATMENT- A COST PER RESPONDER ANALYSIS COMPARED WITH LICENSED BIOLOGICS, FOR MODERATE TO SEVERE PSORIASIS IN ARGENTINA

    Oct 1, 2018, 00:00

  • PND25 - ECONOMIC ANALYSIS OF COMPREHENSIVE REHABILITATION EFFICIENCY WITH AND WITHOUT BOTULINUM NEUROTOXIN A INJECTIONS IN CHILDREN WITH SPASTIC CEREBRAL PALSY

    Oct 1, 2018, 00:00

  • PCV75 - AN UPDATED COST-EFFECTIVENESS PAIRWISE ANALYSIS OF APIXABAN AND WARFARIN FOR STROKE PREVENTION IN PATIENTS WITH NON- VALVULAR ATRIAL FIBRILLATION IN FRANCE

    Oct 1, 2018, 00:00

  • PCP45 - THE ROLE OF CROSSOVER AND TREATMENT SWITCHING IN INDIRECT TREATMENT COMPARSON IN IMMUNO-ONCOLOGY

    Oct 1, 2018, 00:00

  • MD4 - DIGITAL HEALTHCARE EVALUATION AT NICE- AN EVOLVING PROCESS

    Oct 1, 2018, 00:00

  • PSY105 - COST-UTILITY OF NINTEDANIB VERSUS PIRFENIDONE FOR THE TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS- A BELGIAN PERSPECTIVE

    Oct 1, 2018, 00:00

  • PCN153 - COST-EFFECTIVENESS ANALYSIS OF APALUTAMIDE FOR TREATMENT IN NON- METASTASIS CASTRATION-RESISTANT PROSTATE CANCER

    Oct 1, 2018, 00:00

  • PHP271 - THE GROWING IMPORTANCE OF DIGITAL CHANNELS IN FORMULARY DECISION MAKING IN THE US

    Oct 1, 2018, 00:00

  • PSY195 - HUMANISTIC BURDEN ASSOCIATED WITH RPE65 GENE MUTATION RELATED INHERITED RETINAL DYSTROPHIES- A SYSTEMATIC LITERATURE REVIEW

    Oct 1, 2018, 00:00

  • PND142 - FRENCH DATA FROM A WORLDWIDE PATIENT SURVEY ON ECONOMIC IMPACT OF MIGRAINE

    Oct 1, 2018, 00:00

  • PSY49 - BUDGETARY IMPACT OF ORPHAN DRUGS IN THE CATALAN HEALTHCARE SERVICE

    Oct 1, 2018, 00:00

  • PCN103 - PREDICTED TREATMENT COSTS AND SAVINGS PER PATIENT OF KANJINTI® (TRASTUZUMAB BIOSIMILAR) VS. SUBCUTANEOUS (SC) AND INTRAVENOUS (IV) HERCEPTIN® AND OTHER TRASTUZUMAB BIOSIMILARS IN ITALY

    Oct 1, 2018, 00:00

  • PSY154 - ECONOMIC BURDEN OF BETA-THALASSEMIA- LITERATURE REVIEW

    Oct 1, 2018, 00:00

  • PRM39 - IS THE CHOICE OF WILLINGNESS-TO-PAY THRESHOLD IN COST-UTILITY ANALYSIS ENDOGENOUS TO THE RESULTING VALUE OF THE TECHNOLOGY?

    Oct 1, 2018, 00:00

  • PSY80 - THE COST OF HEALTHCARE FOR CHILDREN WITH SICKLE CELL DISEASE- AN ANALYSIS OF HEALTHCARE UTILIZATION AND EXPENDITURES IN THE NETHERLANDS

    Oct 1, 2018, 00:00

  • PCN7 - A TIME WITHOUT SYMPTOMS OR TOXICITY ANALYSIS OF NIRAPARIB COMPARED WITH ROUTINE SURVEILLANCE IN THE MAINTENANCE TREATMENT OF PATIENTS WITH RECURRENT OVARIAN CANCER

    Oct 1, 2018, 00:00

  • PCV155 - EVALUATING THE IMPACT OF PHARMACIST INTERVENTION ON DISEASE KNOWLEDGE, ILLNESS PERCEPTIONS, AND BELIEF TOWARDS MEDICATIONS IN ACUTE CORONARY SYNDROME PATIENTS IN HONG KONG

    Oct 1, 2018, 00:00

  • PCP67 - REGULATORY REQUIREMENTS AND SCIENTIFIC RATIONALE FOR BIOSIMILAR- US VS. EUROPEAN UNION.

    Oct 1, 2018, 00:00

  • PMD31 - THE CONCORDANCE AND BUDGET IMPACT OF MULTIPLE ER, PR AND HER2 DETERMINATIONS IN DUTCH BREAST CANCER PATIENTS

    Oct 1, 2018, 00:00

  • PUK15 - PHARMACOECONOMICS MODES OF ANTIBIOTIC THERAPYOF UNCOMPLICATED COMMUNITY-ACQUIRED ACUTE PYELONEPHRITIS IN A MULTIDISCIPLINARY HOSPITALS

    Oct 1, 2018, 00:00

  • PDB17 - REAL-WORLD DOSING BEHAVIOURS AND OUTCOMES WHEN SWITCHING TO IDEGLIRA FROM A FREE COMBINATION OF INSULIN AND GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST THERAPY

    Oct 1, 2018, 00:00

  • PMS49 - COST-EFFECTIVENESS OF FRACTURE PREVENTION PROVIDED TO ELDERLY LIVING IN THE COMMUNITY

    Oct 1, 2018, 00:00

  • PRM232 - LONGITUDINAL MATCHING- A METHOD FOR GENERATING COMPARABLE SAMPLES OF TREATED AND TREATMENT-NAÏVE PATIENTS WITH PROGRESSIVE CONDITIONS

    Oct 1, 2018, 00:00

  • MD1 - EVIDENCE DEVELOPMENT TIMELINE OF MEDICAL DEVICES IN THE UK- WHERE DO MEDICAL INNOVATION BRIEFINGS FIT?

    Oct 1, 2018, 00:00

  • PRS8 - EFFECTS OF SMOKIMG CESSATION ON HEALTH OUTCOMES AMONG COPD PATIENTS IN SOUTH KOREA- 12 YEARS FOLLOW-UP

    Oct 1, 2018, 00:00

  • PHP148 - SELF-PERCEIVED HEALTH INEQUALITIES BY INCOME DISTRIBUTION IN EUROPEAN UNION

    Oct 1, 2018, 00:00

  • PDB94 - INITIAL ANTIDIABETIC PHARMACOTHERAPY PRESCRIBED TO PATIENTS WITH NEWLY DIAGNOSED TYPE-2 DIABETES IN A COMMERCIAL HEALTH PLAN IN THE UNITED STATED

    Oct 1, 2018, 00:00

  • PRM180 - COMPARING QALYS GENERATED FOR THE EQ-5D-3L AND EQ-5D-5L IN A LONGITUDINAL STUDY OF CANCER PATIENTS

    Oct 1, 2018, 00:00

  • PCN356 - HOW SHOULD WE VALIDATE UTILITY MAPPING ALGORITHMS BEFORE USE? AN EXAMPLE IN NON-SMALL CELL LUNG CANCER

    Oct 1, 2018, 00:00

  • CN8 - COST-EFFECTIVENESS ANALYSIS OF ORAL CANCER SCREENING IN TAIWAN- A REAL WORLD DATA ANALYSIS

    Oct 1, 2018, 00:00

  • PCN377 - RESPONSE SHIFT EFFECT ON QUALITY OF LIFE IN RANDOMIZED CONTROL TRIAL OF TAXANE VERSUS S-1 FOR METASTATIC BREAST CANCER PATIENTS (SELECT-BC)- STRUCTURAL EQUATION MODELING

    Oct 1, 2018, 00:00

  • PHP342 - HOW TO MAXIMIZE THE EX-FACTORY PRICE IN PORTUGAL, WITH SIMULTANEOUS BENEFITS FOR PATIENTS AND PAYERS – AN INDUSTRY PERSPECTIVE

    Oct 1, 2018, 00:00

  • PRM271 - REDUCING LENGTH OF AN OUTCOMES-BASED CONTRACT THROUGH ACTIVE-LEARNING BY PAYERS

    Oct 1, 2018, 00:00

  • PCN352 - UTILITY VALUES FOR ADVANCED HEPATOCELLULAR CARCINOMA PATIENTS IN FRANCE RECEIVING SELECTIVE INTERNAL RADIATION THERAPY (SIRT) WITH Y-90 RESIN MICROSPHERES VERSUS SORAFENIB USING EQ-5D SCORES MAPPED FROM EORTC-QLQ-C30 RESULTS

    Oct 1, 2018, 00:00

  • PDB78 - ECONOMIC EVALUATION OF DAPAGLIFLOZIN AS ADD-ON TO METFORMIN FOR T2DM TREATMENT IN THE ISRAELI HEALTHCARE SETTING

    Oct 1, 2018, 00:00

  • PCN83 - THE USE OF OBINUTUZUMAB IN TREATMENT OF REFRACTORY AND RELAPSING FOLLICULAR LYMPHOMA

    Oct 1, 2018, 00:00

  • PRM125 - SYSTEMATIC REVIEW OF META-MODELING APPLICATIONS AND OPPORTUNITIES FOR ADVANCED ANALYSES WITH HEALTH ECONOMIC MODELS

    Oct 1, 2018, 00:00

  • Researchers, Patients, and Stakeholders Evaluating Comparative-Effectiveness Research- A Mixed-Methods Study of the PCORI Reviewer Experience

    Oct 1, 2018, 00:00

  • PCV31 - ANTICOAGULANTS IN OLDER PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION AFTER INTRACRANIAL HEMORRHAGE

    Oct 1, 2018, 00:00

  • PGI47 - OPIOID USAGE AND PATIENT-REPORTED PAIN SCORES IN IRRITABLE BOWEL SYNDROME PATIENTS- A RETROSPECTIVE ANALYSIS OF A LARGE U.S. ELECTRONIC HEALTH RECORD DATABASE

    Oct 1, 2018, 00:00

  • PHP268 - THE HUNGARIAN PALLIATIVE CARE POSITION, CHALLENGES, BREAK POINTS

    Oct 1, 2018, 00:00
  • «
  • 61
  • 62
  • 63
  • 64
  • 65 (current)
  • 66
  • 67
  • 68
  • 69
  • 70
  • »